N-glycosylation humanization for production of therapeutic recombinant glycoproteins in saccharomyces cerevisiae

12Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The production of therapeutic recombinant glycoproteins deals with three main issues: cost, production capacities, and glycosylation. Nowadays, such proteins are expressed in various complex expression systems (CHO, bacteria, etc.); the processes related to those production hosts are time consuming and expensive, or the question of posttranslational modi fications (as glycosylation) control is still unresolved. There is a need tofind an alternative approach, while maintaining high quality level: the new system must be able to add complex N-glycan structures to proteins of interest. Developed in several strains of Saccharomyces cerevisiae, GlycodExpress TM is an innovative technology that allows production of therapeutic recombinant glycoproteins with humanized and homogeneous N-glycan moieties. We show how to delete mannosyltransferases involved in host N-glycosylation to obtain more than 90% of homogeneity in glycan structures. The methodology developed to select the optimal fusion between a heterologous glycosyl-enzyme and a localization sequence is also presented.finally, the screening of the best producing strain is illustrated. © Springer Science+Business Media New York 2013.

Cite

CITATION STYLE

APA

Arico, C., Bonnet, C., & Javaud, C. (2013). N-glycosylation humanization for production of therapeutic recombinant glycoproteins in saccharomyces cerevisiae. Methods in Molecular Biology, 988, 45–57. https://doi.org/10.1007/978-1-62703-327-5_4

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free